Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency
- PMID: 34664536
- DOI: 10.1080/14740338.2022.1993186
Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency
Abstract
Introduction: Lysosomal acid lipase deficiency is an autosomal recessive progressive lysosomal storage disease that mainly affects the liver, intestine growth, and causes dyslipidemia. The disease presents as two major phenotypes: the severe early-onset and late-onset forms. Sebelipase alfa is a recombinant human enzyme-replacement therapy for lysosomal acid lipase deficiency, which has been approved for long-term treatment of early-onset and late-onset patients over five years.
Areas covered: This review mainly focuses on the safety of sebelipase alfa based on the literature including studies, case reports, and reviews up to January 2021. The search was conducted on PubMed only by using the key word "sebelipase alfa." No restrictions were applied.
Expert opinion: The documented adverse events related to sebelipase alfa almost always occurred as infusion reactions. The majority of these reactions were mild to moderate and were easily managed or prevented with antihistamines, antipyretics, and steroids. Rarely, these reactions occurred in the form of anaphylaxis but were treated successfully and the infusions were started again with desensitization without a need for stopping the treatment. Based on the scientific evidence until now, sebelipase alfa appears to be a safe treatment changing the natural history of lysosomal acid lipase deficiency.
Keywords: Inborn errors of metabolism; lysosomal acid lipase; sebelipase alfa.
Similar articles
-
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.Orphanet J Rare Dis. 2021 Jan 6;16(1):13. doi: 10.1186/s13023-020-01577-4. Orphanet J Rare Dis. 2021. PMID: 33407676 Free PMC article.
-
Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency.Drugs Today (Barc). 2016 May;52(5):287-93. doi: 10.1358/dot.2016.52.5.2488974. Drugs Today (Barc). 2016. PMID: 27376161 Review.
-
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.Orphanet J Rare Dis. 2017 Feb 8;12(1):25. doi: 10.1186/s13023-017-0587-3. Orphanet J Rare Dis. 2017. PMID: 28179030 Free PMC article. Clinical Trial.
-
Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.J Hepatol. 2014 Nov;61(5):1135-42. doi: 10.1016/j.jhep.2014.06.022. Epub 2014 Jun 30. J Hepatol. 2014. PMID: 24993530 Free PMC article. Clinical Trial.
-
Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency.Am J Cardiovasc Drugs. 2016 Dec;16(6):461-468. doi: 10.1007/s40256-016-0203-2. Am J Cardiovasc Drugs. 2016. PMID: 27878737 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
